TerraPower chose Comecer for the factory acceptance test for their groundbreaking technology to make possible a stable supply of the Actinium-225 that is in scarce supply
Comecer has completed a special FAT project for TerraPower's therapeutic radiopharmaceutical facility.
A customised hot cell suite solution has been specifically conceived to enable TerraPower's groundbreaking technology to make possible a stable supply for 225Ac.
Because this End-to-end Hot Cell suite solution has been specifically conceived to enable Terrapower's groundbreaking technology to make possible a stable supply for 225Ac, an alpha-emitting radionuclide with the potential to effectively treat many oncologic diseases when attached to a molecule that will selectively target cancerous tissue and destroy it with minimum damage to nearby healthy cells.
In this day and age, unfortunately, Actinium-225 is in scarce supply globally, limiting drug trials to explore the effectiveness of this crucial radionuclide.
But this FAT project sets the stage for innovator pharmaceutical and biotech companies to further advance their development of important therapeutic radiopharmaceuticals which use Actinium-225 as a critical pharmaceutical ingredient.
"We at Comecer are truly honoured to contribute to such an innovative and critical project, putting our exclusive know-how and technology at the service of our customers, and more extensively to the healthcare and scientific community," the company stated.